Red alarm level: Big passes in drugs in Hesse threaten!

Red alarm level: Big passes in drugs in Hesse threaten!

Hessen, Deutschland - In Hesse there are currently considerable bottlenecks in the supply of drugs. Saline solutions for infusions as well as neurological drugs and means of treating ADHD are particularly affected. Christian Ude, President of the Hessian State Pharmacist Chamber, pointed out the worrying supply problems and stated that bottlenecks in antibiotics and children's medicines were determined last year. However, there are currently no problems to report with children's medicines. The situation raises questions that go beyond regional care.

ude emphasizes that the number of production facilities for drugs is insufficient and that the existing ones would often be unfavorably localized. These facts are all the more alarming, considering the global challenges in drug production. The global political situation contributes to the complexity and makes the dependency on international production facilities increasingly problematic.

background and causes

The availability of medicinal products in Germany is increasingly at risk. Frequent delivery bottlenecks pose great challenges for both patients and medical staff. The main reasons for these bottlenecks include production failures, problems in the supply chains and economic factors. The potential of natural disasters, political unrest and even pandemics means that globalized drug production is more susceptible to disorders. In particular, the concentration of production in just a few countries increases the susceptibility to bottlenecks that can quickly become globally noticeable, as the Pioneer newspaper

Another problem is the immense price pressure in the healthcare system. Medicines are often bought at the lowest prices, which means that manufacturers stop producing less profitable medication. Richard Saynor, the head of Sandoz, emphasized the complexity of the delivery problems and pointed out the need for solutions. These include, for example, the diversification of the production locations and the strengthening of European drug production to shorten the supply chains.

future measures and solutions

In order to ensure reliable pharmaceutical supply, comprehensive measures are required. Experts call for incentives for the production of central medications through government funding as well as the establishment of early warning systems and strategic drug bearings. These strategies could help recognize bottlenecks early and to react better to them. The Federal Institute for Medicines and Medical Devices (BfArM) has already set up a database that records current and resolved delivery bottlenecks of human medicine. This helps to map and analyze the situation transparently.